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MLpA and DnA index improve 
the molecular diagnosis 
of childhood B‑cell acute 
lymphoblastic leukemia
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Meng‑Yao Lu4, Shu‑Huey Chen6, Chao‑Neng Cheng7, Kang‑Hsi Wu8, Shih‑Chung Wang9, 
Hsiu‑Hao chang4, Meng‑Ju Li4,10, Yu‑Ling Ni11, Yi‑Ning Su3, Dong‑Tsamn Lin4,11, 
Hsuan‑Yu chen5, Christine J. Harrison12, Chia‑Cheng Hung3*, Shu‑Wha Lin1* & 
Yung‑Li Yang4,11,13*
Aneuploidy occurs within a significant proportion of childhood B‑cell acute lymphoblastic leukemia 
(B‑ALL). Some copy number variations (CNV), associated with novel subtypes of childhood B‑ALL, 
have prognostic significance. A total of 233 childhood B‑ALL patients were enrolled into this study. 
focal copy number alterations of ERG, IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A/2B, and the 
Xp22.33/Yp11.31 region were assessed by Multiplex Ligation‑dependent Probe Amplification (MLPA). 
the MLpA telomere kit was used to identify aneuploidy through detection of whole chromosome loss 
or gain. We carried out these procedures alongside measurement of DNA index in order to identify, 
aneuploidy status in our cohort. MLPA telomere data and DNA index correlated well with aneuploidy 
status at higher sensitivity than cytogenetic analysis. Three masked hypodiploid patients, undetected 
by cytogenetics, and their associated copy number neutral loss of heterozygosity (CN‑LOH) were 
identified by STR and SNP arrays. Rearrangements of TCF3, located to 19p, were frequently 
associated with 19p deletions. Other genetic alterations including iAMP21, IKZF1 deletions, ERG 
deletions, PAX5AMp, which have clinical significance or are associated with novel subtypes of ALL, 
were identified. In conclusion, appropriate application of MLPA aids the identifications of CNV and 
aneuploidy in childhood B‑ALL.
As the most common pediatric cancer, acute lymphoblastic leukemia (ALL) accounts for approximately 25% of 
childhood malignancies. With improved risk-directed treatment and supportive care, the overall 5-year event-free 
survival rates for this disease now exceed 80% in developed  countries1–3. The two major features of risk-directed 
therapy are based on the genetic alterations of the leukemic cells at diagnosis and the determination of initial 
treatment response (measured by minimal residual disease, MRD, after induction therapy). The interpretation 
of MRD levels depends upon the subtype of  ALL4,5. Although karyotyping has been the most common approach 
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for detection of numerical chromosomal changes, molecular methods may enhance their detection in childhood 
B-ALL. Multiplex Ligation-dependent Probe Amplification (MLPA) is a sensitive method based upon the multi-
plex polymerase chain reaction and capillary electrophoresis that detects multiple copies of around 50 different 
genomic DNA targets. It has the advantage of lower price and quicker turn-around time than DNA arrays for 
identification of the important genetic alterations and is now widely used for detection of the important copy 
number changes in  ALL6,7.
Gain or loss of whole chromosomes (aneuploidy) and intrachromosomal amplification of chromosome 21 
(iAMP21) accounts for almost 30% of childhood B-ALL identified by traditional methods. High hyperdiploidy 
with greater than 50 chromosomes comprises up to 30% of childhood B-ALL and most commonly involves gains 
of chromosomes X, 4, 10, 14, 17 and  218. It is associated with a good outcome, even in patients with induction 
 failure9. Hypodiploidy with less than 44 chromosomes is less common (found in approximately 3% of cases) and 
is associated with an inferior outcome. Hypodiploid B-ALL can be further divided into three subgroups according 
to chromosome number. The most common are near-haploidy with 24–31 chromosomes and low-hypodiploidy 
with 32–39 chromosomes. High-hypodiploidy with 40–43 chromosomes is rare. Low-hypodiploid ALL has a 
high incidence of TP53 germline  mutations10. DNA index (DI) is a well-established method for detection of high 
hyperdiploidy. The MLPA telomere kit identifies specific gain or loss of individual chromosomes and is suitable 
for screening for whole chromosome numerical  changes11,12. Masked low hypodiploidy, manifesting as doubling 
of the low hypodiploid chromosome number, can be difficult to  diagnose13. Here we show that MLPA and DI 
are useful in its detection, as confirmed by single-nucleotide polymorphism (SNP) arrays and short tandem 
repeats (STR). B-ALL patients with iAMP21-ALL were initially shown to have a high relapse risk on standard 
 chemotherapy14,15. It was later demonstrated that treatment on intensive therapy regimens significantly reduced 
their risk of  relapse16–18.
In childhood B-ALL, SNP arrays have successfully identified copy number abnormalities (CNA)19 involving 
several signaling pathways. For example, deletions of a number of genes within the B-cell differentiation pathway 
were identified, including PAX5, EFB1 and IKZF119,20. Clinically, IKZF1 alterations have been associated with 
a poor outcome, particularly in association with Ph-positive (Philadelphia chromosome/BCR-ABL1 positive), 
and Ph-like ALL (Philadelphia chromosome/BCR-ABL1 negative but the expression profiles were similar to 
Ph-positive ALL)20–27. Ph-like and iAMP21-ALL have been proposed as novel subtypes of B-ALL in the recent 
WHO classification of hematologic malignancies, due to their poor prognostic  associations28.
In this project, we have used MLPA and DI to study CNA in B-ALL. We show that these approaches are 
complementary to cytogenetics in improving detection of genetic alterations in childhood B-ALL.
Materials and methods
Patients and protocols. Diagnostic bone marrow (BM) or peripheral blood was obtained from 233 chil-
dren with B-ALL from January 2002 to July 2018 at the National Taiwan University Hospital. A total of 108 
patients were treated on the Taiwan Pediatric Oncology Group TPOG-ALL-2002 protocol, while 125 were 
treated on TPOG-ALL-2013. Diagnosis of B-ALL was based on BM morphology and the immunophenotype of 
leukemic cells was determined by flow cytometry. Conventional cytogenetic analysis was carried out as part of 
the routine work-up29.
The risk-directed TPOG protocols consist of multiple chemotherapeutic agents of different intensities. The 
treatment protocol was intensified if complete remission was not achieved after initial induction therapy. After 
2013, MRD levels were added to risk assignment for therapy. Events were defined as any relapse, death, or second-
ary malignancy. The Institutional Review Board of National Taiwan University Hospital approved the study and 
all of the participants or their guardians provided written informed consent in accordance with the Declaration 
of Helsinki. Details of the protocols and risk group assignment have been published  elsewhere27,30,31. We have 
summarized the risk classification of protocols in the Supplementary information.
Genomic DNA extraction. Lymphoblasts were purified from bone marrow or peripheral blood specimens 
using the Ficoll-Paque centrifugation method, according to the manufacturer’s instructions (GE Healthcare, Pis-
cataway, NJ, USA). Genomic DNA was extracted from leukemic cells using standard phenol/chloroform-based 
methods. Briefly, 1 million cells were lysed in 10 mM Tris–HCl, 10 mM NaCl, 10 mM EDTA, 20 μg proteinase 
K, and 0.5% SDS by incubating at 37 °C for 16 h. Total RNA was further removed by adding 500 μg PureLink 
RNase A (Invitrogen, USA) and incubating for 10 min at 37 °C. An equal volume of phenol–chloroform–isopro-
panol (25:24:1) was added to lysates and mixed by shaking vigorously, followed by centrifugation at 16,100 × g 
at 4 °C for 5 min. The upper aqueous phase was transferred to a fresh tube; genomic DNA was then precipitated 
by adding 2× volume − 80 °C 100% ethanol. The DNA pellet was washed with 75% ethanol and rehydrated with 
Tris–EDTA buffer. The concentration of DNA was determined using a NanoDrop 1,000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA)32.
MLPA analysis. Genomic DNA was analyzed using the SALSA MLPA kit (MRC-Holland, Amsterdam, the 
Netherlands), according to manufacturer’s instructions. The PCR fragments were separated by capillary electro-
phoresis on a Life Technologies 3,500 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). MLPA 
data were analyzed using Coffalyser.Net v.140721.1958 (MRC-Holland, Amsterdam, The Netherlands). Probe 
ratio between 0.75 and 1.3 were considered to be within the normal range. Probe ratio below 0.75 or above 
1.3 indicated deletion or gain, respectively. Probe ratio below 0.25 or above 1.8 indicated biallelic deletion or 
amplification. SALSA MLPA P335 ALL-IKZF1 probemix was used for detection of alterations of EBF1, IKZF1, 
CDKN2A, CDKN2B, PAX5, ETV6, RB1 and BTG1 genes. SALSA MLPA P327 iAMP21-ERG probemix was used 
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for detecting alterations of ERG gene and iAMP21. SALSA MLPA P329 CRLF2-CSF2RA-IL3RA probemix was 
used for detecting P2RY8-CRLF2 (PAR1 deletion).
Analysis of ploidy status. Ploidy status was evaluated by SALSA MLPA P036 Subtelomeres Mix 1 probe 
mix. Whole chromosomal gain or loss was defined when two probes targeting p and q arms of the same chromo-
some were respectively gained or deleted simultaneously. Chromosome 19p deletions were defined when the 
probe targeted the p arm of chromosome 19 was deleted while q arm was normal.
DNA index measured by flow cytometry. Freshly prepared or frozen leukemia samples were used for 
DNA index analysis. Peripheral blood derived from normal healthy individuals was used as controls for diploidy. 
Mononuclear cells were isolated by Ficoll-Paque (GE Healthcare, Chicago, IL, USA) according to the manufac-
turer’s instructions. Three cell suspensions were prepared: tube A was a mixture of leukemia cells and normal 
PBMCs in equal numbers; tubes B and C contained normal PBMCs or leukemia cells alone. Each cell suspen-
sion (2 million cells) was fixed with 70% ethanol overnight at – 20 °C. Fixed cells were washed with 1× PBS and 
then incubated with propidium iodide (50 μg) and RNase (10 μg) for 1 h on ice. Cells were filtered with 100 μm 
cell strainer and then analyzed by FACSCalibur (BD, Franklin Lakes, NJ, USA). DNA quantity of an individual 
cell population was determined and DNA index represents the ratio of leukemia sample/normal PBMCs fluo-
rescence calculated from tube A. Tubes B and tube C were used as reference to distinguish the leukemia from 
PBMC peaks in tube A. Theoretical DNA index (tDI) was calculated using the formula: tDI = chromosome 
numbers × 0.0202 + 0.067533.
Statistical analysis. Pearson’s correlations, the coefficient of determination and p-values were carried out 
between the results of DI and tDI from MLPA and cytogenetics. Fisher’s exact test was performed to evaluate the 
enrichment of 19p deletion in TCF3 gene rearranged ALL. The log-rank test compared different survival curves 
between patients with different major genetic subtypes, patient with or without IKZF1 deletion and patients with 
or without IKZF1plus. Overall survival (OS) was defined as diagnosis to death. Patients who did not suffer any 
adverse events within the follow-up period were censored. Event-free survival (EFS) of patients with no response 
to chemotherapy (refractory), death, and second relapse in induction was set to 0. Univariate and multivariate 
Cox regression were performed to evaluate hazard ratios (HR) and 95% confidence intervals (CI) of risk factors. 
All statistical analyses were performed using the Statistical Product and Services Solutions (SPSS) statistical 
package, v18.0 (IBM, Armonk, NY, USA).
Results
Frequency of copy number abnormalities in children with B‑ALL. The demographic, clinical, and 
laboratory characteristics of 233 children with B-ALL are shown in Table 1. The median age of the cohort was 
5.4 years (range < 0.1–17.9 years); 95.3% of the patients were over 1 year of age. The molecular tests performed 
were those standardized for B-ALL diagnosis including: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, P2RY8-CRLF2 
and KMT2A-AFF1 for 220 samples. Detailed flow diagram of analysis used in this study is demonstrated in Sup-
plementary Fig. S1.
From MLPA testing, overall, 65.7% of the patients (153/233) harbored at least one abnormality (either deletion 
or amplification) involving the following genes—IKZF1, CDKN2A/2B, PAX5, EBF1, ETV6, BTG1, RB1, ERG or 
PAR1 region, whereas the remaining 34.3% (80/233) of patients had none of these abnormalities. Simultaneous 
aberrations in different genes were observed. A heatmap listing these CNA in the entire cohort are given in Fig. 1. 
Details of the CNA in each major cytogenetic subtype are shown in Supplementary Table S2.
DNA index identifies ploidy status in ALL. In 112 samples DNA index analysis was performed; 41 cases 
showed aneuploidy, of which 35 were high hyperdiploid, 3 were hypodiploid and in 3 cases masked hypodiploidy 
was indicted, as described below. However, DI cannot identify individual chromosome gain or loss.
MLPA compared to DI and cytogenetics. Good quality genomic DNA was available from 204 sam-
ples for MLPA analysis using the MLPA P036 kit which identified 57 patients with high hyperdiploidy, 7 with 
hypodiploidy and 140 with diploidy or near-diploidy. The numerical chromosomal alterations determined by 
this MLPA P036 kit were compared with the karyotype and DI results. These results showed concordance in 
number of chromosomes (r = 0.9780, P < 0.0001) for the 111 patients with both MLPA and DI data available 
(Fig. 2a). There was statistically significant positive correlation between karyotype and DI (r = 0.3308, P = 0.0005) 
(Fig. 2b), yet lower than MLPA against DI, among 188 patients with karyotype and MLPA data available. The 
statistically significant positive correlation was also seen between karyotype and MLPA (r = 0.4428, P < 0.0001) 
(Fig. 2c), but lower than MLPA against DI. We found that 45% (29/64) of patients with high hyperdiploidy or 
hypodiploidy identified either by DI or MLPA P036 were non-informative. Details of karyotype, DI and MLPA 
of the cohort are listed in Supplementary Table S3.
High hyperdiploidy. Among 57 cases with high hyperdiploidy, the majority (94.5%) had gained between 
5 and 13 chromosomes (modal chromosome number, MCN, 51–63, inclusive), and the most frequent MCN 
was 54 chromosomes (Supplementary Fig.  S2a). Chromosome gains were non-random and 8 chromosomes 
accounted for 82% of all gains: 4 (72.7% of cases), 6 (80.7%), 10 (84.2%), 14 (93.0%), 17 (80.7%), 18 (86.0%), 
21 (100%), and X (78.9%) (Supplementary Fig. S2b). Gains of chromosomes 5, 8, 9, 11, 12, and 22 represented 
15% of the total and were present in between 11 and 35% of cases. Gains of chromosomes 1, 2, 3, 7, 13, 15, 16, 
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19, and 20 were rare, totaling 3% of chromosomes gained. These patterns of chromosomal gains in these high 
hyperdiploid cases were similar to previous reports.
The MLPA pattern of iAMP21 and differentiation between iAMP21 and high hyperdip‑
loidy. From their MLPA plots, we identified four patients with iAMP21, as shown in Supplementary Fig. S3. 
A characteristic chromosome 21 copy number profile has been previously described for cases of iAMP21-ALL 
from microarray studies and next generation sequencing. It is described as copy number changes from cen-
tromere to telomere along chromosome 21, with the highest level of amplification proximal to a telomeric 
 deletion34–36. Tsuchiya et al. reported a case in which RUNX1 was not located within the highest region of ampli-
fication of chromosome  2137. In this cohort, RUNX1 was observed within the most highly amplified region of 
chromosome 21, with the exception of one case (Supplementary Fig. S3). In high hyperdiploid cases, the DI 
is usually greater than 1.16 and associated with frequent gains of chromosomes 4, 6, 10, 14, 18, 21 and X. We 
compared the pattern of chromosome 21 gain in high hyperdiploid and iAMP21-ALL in our cohort. SNP arrays 
analysis was carried out on two iAMP21-ALL samples diagnosed by MLPA (Supplementary Fig. S4). For cases 
with suspected iAMP21, in the absence of SNP arrays, DI and MLPA P036 and P327 kits can provide the defini-
tive answer.
Hypodiploid cases. Five patients with low DI were diagnosed with hypodiploidy. Three of them had two 
peaks in the DI, indicating the presence of hypodiploid clone undergo a doubling of the chromosomes during 
metaphase. This manifestation is known as masked hypodiploidy. As the diagnosis of masked hypodiploidy 
requires demonstration of loss of heterozygosity (LOH), these three samples were analyzed by SNP arrays and 
LOH was seen, as shown in case 984 (Fig. 3). DI showed two peaks: the smaller one (FL2-A value = 202) is the 
true hypodiploidy and the higher one (FL2-A value = 393) indicates the doubled hypodiploid population. These 
Table 1.  The characteristics of patients in this cohort. a Only patients treated with TPOG-2013 were included 
(n = 111). Fourteen patients were excluded due to missing data; MRD positive: either MRD > 1% at day 15 
or > 0.01% at day 35.
N %
Sample size 233 100
Gender
< 1 year 11 4.7
1–9 years 160 68.7
> 10 years 62 26.6
Sex
Female 113 48.5
Male 120 51.5
WBC (× 109/l)
< 50 164 70.4
50–100 28 12.0
> 100 38 16.3
No data 3 1.3
Protocol
TPOG 2002 108 46.4
TPOG 2013 125 53.6
Early treatment responsea
MRD positive 30 27.0
MRD negative 81 73.0
Subtype
Hyperdiploidy 59 25.3
Hypodiploidy 7 3.0
ETV6-RUNX1 36 15.5
TCF3-PBX1 12 5.2
Ph+/Ph-like 16 6.9
KMT2A-r 14 6.0
ZNF384/362-r 9 3.9
MEF2D-r 3 1.3
TCF3-HLF 2 0.9
iAMP21 4 1.7
Other 71 30.5
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hypodiploid samples were also tested using MLPA P036 kit. By comparing MLPA with the value of DI, we were 
able to identify the specific losses and retention of each chromosome number. Thus, we were able to confirm that 
the masked hypodiploid population originated from doubling of the low hypodiploid one. In Fig. 3, the chro-
mosome gains detected by MLPA P036 corresponded to the retained chromosomes. In contrast, the “normal” 
chromosomes, for example chromosomes 3, 4, 5, 7, 8, 9, 13, 15, 16, 17 and 20 were shown to be lost. The actual 
gain or loss of each chromosome cannot be inferred from the DNA index. Using the MLPA P036 kit, we identi-
fied another two cases of hypodiploidy (patients 508 and 753) in which LOH was confirmed by STR (see below). 
Details of these patients are listed in the Table 2.
A Short Tandem Repeat (STR) is a microsatellite, consisting of a unit of two to thirteen nucleotides repeated 
hundreds of times on a DNA strand. STR analysis measures the precise number of repeating units. STR is used 
for confirmation of donor engraftment following stem cell transplantations and this test is available in all medi-
cal  centers38. Samples of germline (if available) and tumor were sent for STR analysis in order to confirm LOH 
identified on SNP arrays. We show the interpretation of STR for patient 984 in Supplementary Fig. S5 and all 
three cases of masked hypodiploidy by STR are shown in Supplementary Table S4. STR provides a simple method 
to confirm the presence of LOH. Based upon these observations, we have proposed a flowchart for diagnosis of 
masked hypodiploidy (Supplementary Fig. S6).
19p deletion by MLPA is an indicator of TCF3 translocations in childhood ALL. We identified 
7 of 12 cases of TCF3-PBX1 and two cases of TCF3-HLF with 19p loss. This enrichment differs from other 
subtypes of B-cell ALL (P < 0.0001) (Table 3). TCF3 is an important transcriptional factor with multiple fusion 
partners in ALL. Samples with 19p deletions without evidence of TCF3-PBX1 or TCF3-HLF fusions may carry 
Figure 1.  The heatmap of major subtype of childhood B-cell ALL and the association with CNA detected by 
MLPA. Ph+ BCR-ABL1 positive, No. number, CN copy number.
Figure 2.  Correlation of the DI and tDI from MLPA P036 and karyotype. (a) DI vs. tDI(MLPA P036) 
(r = 0.9780, P < 0.0001). (b) DI vs. tDI (Karyotypes) (r = 0.3308, P = 0.0005). (c) tDI (Karyotypes) vs. tDI (MLPA 
P036) (r = 0.4428, P < 0.0001). tDI theoretical DNA index.
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Figure 3.  Analysis of a case with masked hypodiploidy. (a) The result of MLPA P036. The probe ratio values 
between 0.75 and 1.3 or greater than 1.3 were indicated with green or orange dots respectively. (b) The result of 
CytoScan array. Weight log2 ratio and B-allele frequency (BAF) plots are shown. The BAF plot show only two 
tracts indicate a region with LOH and the whole chromosome LOH is indicated by purple lines. (c) The result of 
DNA index analysis. H hypodiploidy, MH masked hypodiploidy.
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TCF3-ZNF384 fusions. TCF3-ZNF384 fusions represent another important subtype of B-cell ALL with a specific 
immunophenotype showing frequent CD10 loss and CD13 and CD33 expression. From these observations, 
we observed one sample with 19p loss, loss of CD10, CD13 and CD33 expression in which the TCF3-ZNF384 
fusions was identified by RT-PCR (Supplementary Fig. S7). In this series, among a total of 15 samples with 19p 
loss, 10 of them had TCF3 fusions.
Novel subtypes of ALL, intragenic amplifications of PAX5 (PAX5AMp), IKZF1‑plus and ERG 
deletions. Recently two papers have reported two novel high-risk subtypes of childhood ALL, PAX5AMP 
and IKZF1plus7,39. There were 23 IKZF1plus patients and 5 patients with PAX5AMP in this cohort. Nine patients 
(9/233 = 3.9%) were identified with ERG deletions. These ERG deletions were associated with different subtypes 
of ALL (Fig. 1).
Survival analysis. Among patients with the major cytogenetic alterations, two with TCF3-HLF relapsed and 
died within 5 years from diagnosis. Patients with high-risk subtypes (Ph-positive/-like, hypodiploidy, MEF2D-r, 
KMT2A-r, TCF3-HLF, iAMP21) had inferior 5-year EFS (P < 0.0001) and OS (P < 0.0001) (Fig. 4a, b). The overall 
outcome was slightly inferior compared to previous TPOG reports, likely due to many of them being referred 
from other hospitals after  relapse30. All patients with iAMP21 were not detected at diagnosis. There is a trend 
that patients with IKZF1plus had inferior 5 year-EFS and OS than patients without IKZF1plus, but it did not reach 
statistical significance (Fig. 4c, d). Patients with IKZF1 deletions had inferior 5-year EFS and 5-year OS, but it 
also did not reach statistical significance (Fig. 4e, f). In the Cox multivariate regression model, IKZF1 deletions 
were not a strong predictor of poor outcome (Supplementary Table S5).
Discussion
In this retrospective study, the MLPA P036 subtelomeres probemix kit provided accurate detection of aneuploidy 
in childhood B-cell ALL and good correlation with the results from DI. MLPA and DI are superior to tradi-
tional cytogenetics, due to the shorter turn-around time, irrespective of mitotic index and improved sensitivity. 
Detections of specific gains or losses of each chromosome assist the differential diagnosis of hyperdiploidy from 
iAMP21. In addition, DI is helpful for diagnosis of masked hypodiploidy and LOH should be confirmed by SNP 
arrays. STR provides a simple method, available in most medical centers in Taiwan, to document LOH in these 
Table 2.  Detailed information of hypodiploidy cases.
ID Subtype Karyotype MLPA P036 DNA index TP53 mutation
925 High-hypodiploidy 42,X,-4,-9,-13,t(14;17)(q32;p11.2),add(21)(p11.2)[16]/84,idem × 2[3]/46,XY[1] 42,Y,-4,-9,-13 0.91 R248Q (Unknown)
774 Low-hypodiploidy 46,XY[25] 38,XY,-2,-3,-12,-13,-14,-15,-16,-17 0.82 F341fs (Somatic)
508 Low-hypodiploidy 46,XY[20] 32,XY,-2,-3,-4,-6,-7,-9,-10,-12,-15,-16,-17,-18,-20,-22 NA I195F (Germline)
984 Masked Low-hypodiploidy
63,XX,-X, + 1,-3,add(3)(q13),del(3)(q?21),-4,-
5, + 6,-7,-9,-9,-10, + 12,-13, + 14,-15,-16,-17,-
20, + add(21)(q22) × 2, + 22, + 2mar,inc[cp14]/46,
XX[6]
33,XX,-3,-4,-5,-7,-8,-9,-10,-11,-13,-15,-16,-17,-20 0.79/1.54 R273H (Germline)
845 Masked Low-hypodiploidy
68,XX,-Y, + 1,-2,-3,-4,del(4)(q21q31),del(5)
(q13q33), + 6,-7, + 8, + 9,-10, + 11,-12,-13, + 14,-15,-
16,-17,-18, + 19, + 20, + 21, + 22,inc[cp5]/46,XY[20]
34,Y,-2,-3,-4,-7,-10,-12,-13,-15,-16,-17,-18 0.76/1.43 W53* (Somatic)
952 Near-haploidy 26,XY,-1,-2,-3,-4,-5,-6,-7,-8,-9,-11,-12,-13,-14,-15,-16,-17,-18,-19,-20,-22[13]
26,XY,-1,-2,-3,-4,-5,-6,-7,-8,-9,-11,-12,-13,-14,-15,-
16,-17,-18,-19,-20,-22 0.56 Wild-type
753 Masked Near-haploidy 52–54,XX, + mar1 ~ mar8[cp4]/46,XX[21] 27,X,-1,-2,-3,-5,-6,-7,-9,-10,-11,-12,-13,-15,-16,-17,-18,-19,-20,-22 1.17 Wild-type
Table 3.  The 19p deletion in TCF3 translocation and non-TCF3 translocation subtypes. Fisher’s exact test of 
comparing TCF3 translocation with non-TCF3 translocation subtypes, P < 0.0001.
19p Normal 19p Deletion
TCF3 translocation 7 10
TCF3-PBX1 5 7
TCF3-HLF 0 2
TCF3-ZNF384 2 1
Non-TCF3 translocation 162 5
Hyperdiploidy 55 3
ETV6-RUNX1 22 1
KMT2A fusions 11 1
Other 74 0
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masked hypodiploid cases. Around 1.7% (4/233) of B-ALL patients had iAMP21. We also identified some of 
the novel ALL subtypes, including PAX5AMP, and IKZF1plus7,39. TCF3 rearrangements were frequently associated 
with 19p deletions.
High hyperdiploidy accounts for around 20 ~ 25 percentage of childhood B-cell  ALL40. In this cohort, the most 
frequent modal chromosome number was 54 followed by 55. The most frequent gains included chromosomes 
4, 6, 10, 18, 16, 17, 18, 21 and X, in agreement with previous  reports8,40,41. This incidence of high hyperdiploidy 
was lower in Taiwan than Caucasian  populations30,42,43. Using DI and the MLPA P036 kit, the incidence was 
Figure 4.  Five-year EFS and OS analysis. (a, b) Major genetic subtypes. (c, d) IKZF1plus-Positive vs. IKZF1plus-
Negative. (e, f) IKZF1-DEL vs. IKZF1-WT. EFS event-free survival, OS overall survival, DEL deletion, WT wild 
type.
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around 27% in this cohort. In this study, 45% of high hyperdiploid patients were not detected by cytogenetics, 
manifesting as normal karyotype. In previous TPOG ALL 2002 report, hyperdiploidy accounted for 13.6% in 
B-ALL (n = 1,209). The incidence was much lower than that of this report. The reason for this discrepancy might 
be the relative smaller case numbers in this study. For cases without metaphases or normal karyotype, DI and 
MLPA can be successfully used for diagnosis of high  hyperdiploidy11.
iAMP21-ALL is a novel subtype of B-ALL proposed by  WHO14,15,28,33. The initial gold standard for diagnosis 
was FISH using probes directed to the RUNX1 gene, but array-CGH or SNP arrays are now the main method 
for  diagnosis33. One MLPA kit can successfully identify iAMP21 due to the density of probes along the long arm 
of chromosome 21. We identified 4 cases with iAMP21 by MLPA. In these cases, the level of gain was variable 
along the length of chromosome 21 with the ratio being more than 3.0, higher than in cases where chromo-
some 21 is gained as part of a high hyperdiploidy karyotype in which the probe ratio for every probe in the kit 
being ~ 1.5–2.0. These data correlated with other gains, especially of chromosomes 4, 6, 10, 18, 16, 17, 18 and X. 
If gains of chromosomes X, 4, 6, 10, 14, 17 and 18 are detected at the same time as gains of 21, it is most likely 
that the patient has high hyperdiploidy rather than iAMP21-ALL.
Masked hypodiploidy can be difficult to diagnose. Another study used a similar MLPA approach to identify 
the aneuploidy status of relapsed B-cell  ALL12. Three patients with high hyperdiploidy had the highest number of 
chromosomal gains (median 11). Gains of the classical high hyperdiploidy pattern were less frequent, but gains 
of non-classical chromosomes, especially 1, 5, 11, 19 and 22, accounted for 49% of all gains in these patients. All 
three patient relapse samples carried TP53 mutations, two of which were present in the germline. In all three 
cases, no underlying hypodiploid clone was detected by DI or cytogenetic analyses, making diagnosis difficult. 
A recent report by Carroll et al. demonstrated that a considerable proportion (25% or higher) of hypodiploidy 
in children with B-ALL may have been overlooked in previous studies due to the presence of only a doubled 
hypodiploid population, mistakenly interpreted as typical high hyperdiploidy associated with a favorable  risk44. 
In this cohort, the chromosome number in high hyperdiploidy was mostly in the range of 52 ~ 59, which could 
overlap with masked hypodiploidy. For masked hypodiploid cases, the MLPA P036 kit results, alongside DNA 
index, can detect the specific gain or loss of each chromosome. LOH can also be confirmed by STR.
TCF3, located to 19p, is rearranged with several genes in childhood ALL. The most frequent is TCF3-PBX1 
and rarely the poor risk TCF3-HLF2. We observed 19p loss in all TCF3-PBX1 and TCF3-HLF cases. TCF3 has 
also been identified to be rearranged with ZNF384, a novel fusion recently  identified45–48. In cases with 19p dele-
tions without TCF3-PBX1 or TCF3-HLF detected by RT-PCR or cytogenetics, 19p deletions may point to other 
TCF3 fusions. TCF3-ZNF384 fusions are also frequently associated with CD10 loss, with the presence of CD13 
and  CD3345,48,49. These two characteristics are useful for its identification by RT-PCR.
In our cohort, patients with iAMP21 and KMT2A fusions had an inferior 5-year EFS and OS in comparison 
to patients with ETV6-RUNX1 or high hyperdiploidy. Patients with hypodiploidy also had an inferior 5-year 
EFS and OS, although most of them were not identified at the time of diagnosis. The outcome for patients with 
iAMP21-ALL may be improved if detected at diagnosis, so that they may be treated with more intensive chemo-
therapy. No events were seen in patients with PAX5AMP, while patents with IKZF1plus showed a trend towards 
inferior EFS and OS, although the P-value was not significant. IKZF1 deletions showed a trend towards poorer 
clinical outcomes, as observed in a number of other  studies22,27,50. Due to the relative small case numbers in this 
study, larger studies are indicated in Taiwan in order to evaluate the clinical impact of these genetic alterations 
in Taiwan.
In conclusion, MLPA and DNA index together can rapidly provide reliable information for identification of 
aneuploidy of childhood B-ALL. Using these methods, diagnosis of aneuploidy in Taiwan might be improved 
particularly among those cases currently classified within unknown subtype of B-cell ALL, and especially those 
without metaphases or normal karyotype. STR provides a simple method to demonstrate LOH if masked hypo-
diploidy is suspected. Other important abnormalities such as IKZF1 deletions, IKZF1plus and ERG deletions can 
also be identified by MLPA. These tools are helpful for the diagnosis of some important subtype of ALL.
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